Metabolic5AM
Single or box
Loading product
Loading product
Metabolic · Research material
Package information
For product inquiries and additional information, contact lonestarpeptideco@gmail.com.
Compliance notice: For laboratory research use only. Not for human or veterinary use.
Product information is intended for laboratory, academic and commercial researchers aged 18 or over.
Material profile
A GLP-1 backbone analogue bearing a palmitoyl group attached through a gamma-glutamyl spacer at lysine 26, with arginine substituted at position 34. Supplied as a lyophilized powder at 10 mg in one vial. A box of 10 is available as an optional package. It is stocked as a reference material for receptor-binding assays, LC-MS method development and in-vitro screening panels. For laboratory research use only. Not for human or veterinary use.
Catalog record
| Product | Liraglutide — 10 mg |
|---|---|
| Catalog SKU | LRG10 |
| Compound | Liraglutide |
| Appearance | Lyophilized white powder |
| Fill per vial | 10 mg |
| Storage condition | -20 °C, desiccated, protect from light |
Laboratory handling
Ships as a sealed, stoppered lyophilized vial under insulated cold pack. Hold at -20 degrees C, desiccated and protected from light; acylated peptide analogues of this class are hygroscopic and will pick up atmospheric moisture if the stopper seal is broken. Allow vials to equilibrate to ambient temperature before the seal is opened, and follow the receiving laboratory's own written handling and disposal protocols.
Evidence first
This listing does not currently publish lot-specific analytical results. Request and review the applicable documentation before using the material in laboratory work.
Published literature
Liraglutide is a 31-amino-acid acylated analog of human glucagon-like peptide-1 (GLP-1), sharing 97% sequence identity with native GLP-1(7-37). Its structure carries an Ala8-to-Gly substitution that confers resistance to DPP-4 enzymatic cleavage, plus a C16 fatty-acid moiety attached via a glutamic-acid spacer to a lysine side chain, conferring high-affinity, near-total albumin binding. Biophysical studies describe lipidation as increasing the peptide's alpha-helical content and promoting self-association into defined oligomeric species that influence its absorption kinetics and stability profile, with beta-sheet-rich fibril formation described under stressed aging conditions in vitro. Pharmacokinetic characterization describes an elimination half-life of approximately 13 hours, attributed to the combination of self-association, albumin binding, and DPP-4 resistance. Liraglutide is an approved pharmaceutical compound; this entry is restricted to its molecular structure, receptor-binding chemistry, and pharmacokinetic/stability profile, and does not summarize or cite any population-level or outcome-based trial data.
Describes what the cited studies examined in the systems noted above — not a claim about outcomes for people. Not medical advice.
Product support
No downloadable certificate is currently attached to this listing. Email lonestarpeptideco@gmail.com if your laboratory requires lot-specific documentation for review.
Use the package selector to review the single-vial and box-of-10 formats, then use Email to inquire if you want to ask about that product.
The catalog storage condition is -20 °C, desiccated, protect from light. Follow the handling information on this page and your laboratory's written procedures.
No. It is presented only as laboratory research material and is not for human or veterinary use, food, drugs, cosmetics, household use, or self-administration.
Catalog navigation
Other catalog records grouped under the same editorial collection.
Product inquiries
Contact Lone Star Peptide Co. for product information and inquiries.
Email to inquireRequired notice
For laboratory research use only. Not for human or veterinary use, food, drugs, cosmetics, household use, or self-administration. Product information is provided for material identification, handling, and analytical documentation; it is not medical advice or a statement of clinical safety or effectiveness.
